focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Europe down after Easter holiday weekend

Tue, 02nd Apr 2024 16:57

(Alliance News) - The FTSE 100 took a hit on Tuesday, after a boost from London's miners and oil firms were not enough to lift the index.

The FTSE 100 index closed down 17.53 points, 0.2%, at 7,935.09. The FTSE 250 ended down 170.84 points, 0.9%, at 19,713.89, and the AIM All-Share closed down 0.86 of a point, 0.1%, at 742.40.

The Cboe UK 100 ended down 0.3% at 793.40, the Cboe UK 250 closed down 1.1% at 17,147.56, and the Cboe Small Companies ended down slightly at 14,553.13.

In European equities on Tuesday, the CAC 40 in Paris ended down 0.9%, while the DAX 40 in Frankfurt ended down 1.1%.

After a long Easter weekend, markets reopened on Tuesday to a busy day on the corporate and economic calendar.

Data from S&P Global on Tuesday showed the UK manufacturing sector crossing the no-change mark into growth territory in March.

The seasonally adjusted S&P Global UK manufacturing purchasing managers' index reading was 50.3 points in March, up from 47.5 in February and beating the earlier flash estimate of 49.9.

The latest figure was above the 50-point no-change mark, meaning the UK manufacturing sector returned to growth territory.

PMI data from the eurozone was more disheartening, however.

The latest Hamburg Commercial Bank manufacturing PMI fell to 46.1 points in March, from 46.5 in February. The latest reading was a three-month low, but topped the flash estimate of 45.7 points.

Hamburg Commercial Bank analyst Cyrus de la Rubia commented: "It's a bit disheartening: over the last eight months, the manufacturing industry has been gradually climbing the output PMI ladder, but it still finds itself on the basement staircase."

More positively for the eurozone, Germany saw inflation ease in March.

The consumer price index rose by 2.2% annually in March, ebbing from a 2.5% rise in February. This came in line with FXStreet-cited market consensus and is the lowest value since April 2021.

Analysts at ING said: "despite the early timing of Easter this year, prices for leisure, packaged holidays and hotels and restaurants rose less than expected month-on-month than expected. The Easter bunny effect, ie the base effect stemming from the timing of Easter, was hardly visible this year."

The pound was quoted at USD1.2564 at the London equities close Tuesday, lower compared to USD1.2640 at the close on Thursday. The euro stood at USD1.0771 at the European equities close Tuesday, down against USD1.0803 at the same time on Thursday. Against the yen, the dollar was trading at JPY151.60, up compared to JPY151.29 late Thursday.

In the FTSE 100, miners were among the better large-cap performers. Fresnillo, Anglo American, Glencore, and Rio Tinto traded 7.6%, 4.6%, 3.0%, and 2.0% higher respectively.

The miners got a boost from the latest set of PMI data from China. Monthly factory activity in China grew for the first time in half a year, official figures showed, in a positive sign for policymakers seeking to revive the world's second-largest economy.

The PMI came in at 50.8 points in March, according to the National Bureau of Statistics, up from 49.1 in February. The last expansion in China's monthly PMI was in September, with factory activity consistently negative since then, according to NBS data.

The trend of improvement was confirmed by the Caixin manufacturing PMI, which edged up to 51.1 from 50.9.

Oil firms also did well on Tuesday, on the back of higher oil prices. Shell and BP rose 3.2% and 2.5% respectively.

Brent oil was quoted at USD88.11 a barrel at the London equities close Tuesday, up from USD86.56 late Thursday.

"The ongoing rise in oil prices amid a tighter supply outlook is a worry for corporates and consumers as it is a major inflationary force," said Russ Mould, investment director at AJ Bell.

On the other hand, housebuilders were in the red. Taylor Wimpey, Persimmon, and Barratt Developments lost 3.1%, 3.5%, and 0.1%, respectively.

They were hit by a fall in house prices in the most recent month.

The Nationwide house price index showed a 0.2% decline in seasonally adjusted UK house prices in March from February, compared to a 0.7% rise in February from January. According to FXStreet, market consensus expected the house price index to rise 0.3% last month.

Annually, the house price index rose 1.6% in March compared to a year ago, improving from an annual rise of 1.2% in February, but undershooting FXStreet-cited expectations of a 2.4% rise.

Elsewhere in London, on AIM, Orcadian Energy surged 86%.

The oil and gas development company said it has completed the farm-out of 81% interest in Licence P2244, which contains the Pilot field, to Ping Petroleum UK PLC. Ping is focused on shallow water offshore production, and has a significant acreage holding to the East of Pilot.

On the other hand, Redx Pharma plummeted 65%, after it said it intends to cancel its shares from trading on AIM in London.

The clinical-stage biotechnology company said the board unanimously concluded that it is in the best interests of the company to re-register as a private limited company, as it is "still liquidity constrained" on AIM.

Chair Jane Griffith said: "The board believes that as a private company we can access a broader universe of specialty investors and, accordingly, a larger quantum of future funding required to execute our strategy and maximise our value in the interests of all our shareholders."

Stocks in New York were lower at the London equities close, with the DJIA down 1.1%, the S&P 500 index down 0.9%, and the Nasdaq Composite down 1.2%.

Gold was quoted at USD2,266.55 an ounce at the London equities close Tuesday, up against USD2,221.01 at the close on Thursday.

In Wednesday's UK corporate calendar, there are full year results from Hilton Food, Impax Environmental Markets, and Pantheon Infrastructure.

The economic calendar for Wednesday has unemployment and CPI data from the eurozone out at 1000 BST.

There are also a number of Federal Reserve members who are scheduled to speak, including Fed Chair Jerome Powell, Vice Chair Michale Barr, Governor Michelle Bowman, and Governor Adriana Kugler.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
13 Dec 2022 15:53

UK earnings, trading statements calendar - next 7 days

Wednesday 14 December 
Cohort PLCHalf Year Results
CyanConnode Holdings PLCHalf Year Results
Foresight Sustainable Forestry Co PLCFull Year Results
IntegraFin Holdings PLCFull Year Results
SThree PLCTrading Statement
Tui AGFull Year Results
Watches of Switzerland Group PLCHalf Year Results
Thursday 15 December 
Biffa PLCHalf Year Results
C4X Discovery Holdings PLCFull Year Results
Currys PLCHalf Year Results
Libertine Holdings PLCHalf Year Results
RWS Holdings PLCFull Year Results
Serco Group PLCTrading Statement
Friday 16 December 
Gore Street Energy Storage Fund PLCHalf Year Results
Hollywood Bowl Group PLCFull Year Results
Monday 19 December 
Thruvision Group PLCHalf Year Results
Tuesday 20 December 
Jersey Electricity PLCFull Year Results
Petrofac LtdTrading Statement
Redx Pharma PLCFull Year Results
  
Copyright 2022 Alliance News Ltd. All Rights Reserved.

Read more
11 Nov 2022 15:24

TRADING UPDATES: De La Rue defends chair; Resolute Mining fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
11 Oct 2022 14:51

TRADING UPDATES: Scirocco repays loan; Vp says rail strikes slow works

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Oct 2022 22:06

TRADING UPDATES: Blencowe Resources sees potential interest from China

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
5 Aug 2022 13:58

Redx Pharma staff sell 1.5 million shares via accelerated bookbuild

(Alliance News) - Redx Pharma PLC on Friday confirmed that Chief Scientific Officer Richard Armer and other current and former employees have sold a total of 1.5 million shares at 59 pence each via an accelerated bookbuild.

Read more
3 Aug 2022 17:57

IN BRIEF: Redx Pharma employees to sell at least GBP605,120 in shares

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Chief Scientific Officer Richard Armer and other current and former employees look to sell 1.5 million shares at a minimum price of 59 pence each via an accelerated bookbuild, which is 11% discount to Tuesday's closing price of 66.50p.

Read more
27 Jun 2022 16:01

IN BRIEF: Redx Pharma reports "encouraging" fibrosis treatment data

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes encouraging preclinical data for the potential of its Porcupine and ROCK inhibitors to tackle cancer-associated fibrosis. Further data supported the ROCK inhibitor as a potential treatment for fibrostenotic Crohn's disease.

Read more
23 Jun 2022 11:29

IN BRIEF: Redx Pharma narrows half-year loss as pipeline progresses

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - In the half year ended March 31, pretax loss narrows to GBP9.7 million from GBP12.7 million year-on-year. Revenue multiplies to GBP8.4 million from GBP2.1million. Reports strong progress across its pipeline, especially its lead oncology asset RXC004 moving into phase II clinical trials, and its lead fibrosis asset, RXC007, reporting "encouraging" phase I safety data. Says its Rock inhibitor RXC008 has the potential to become a first-in-class treatment for fibrostenotic Crohn's disease, and is likely to be ready to enter the clinic by the end of next year.

Read more
16 Jun 2022 16:05

UK earnings, trading statements calendar - next 7 days

Friday 17 June 
Tesco PLCQ1 Results
Monday 20 June 
Associated British Foods PLCQ3 Results
SysGroup PLCFull Year Results
SThree PLCTrading Statement
Tuesday 21 June 
DS Smith PLCFull Year Results
Gear4Music PLCFull Year Results
Monks Investment Trust PLCFull Year Results
Record PLCFull Year Results
Safestore Holdings PLCHalf Year Results
Telecom Plus PLCFull Year Results
Wednesday 22 June 
Berkeley Group Holdings PLCFull Year Results
Liontrust Asset Management PLCFull Year Results
Micro Focus International PLCHalf Year Results
Thursday 23 June 
DeepVerge PLCFull Year Results
First Property Group PLCFull Year Results
Manolete Partners PLCFull Year Results
Naked Wines PLCFull Year Results
Oxford Metrics PLCHalf Year Results
Redx Pharma PLCHalf Year Results
Serco Group PLCTrading Statement
Volex PLCFull Year Results
XPS Pensions Group PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
15 Jun 2022 10:24

Redx Pharma rises on FDA clearance for solid tumour treatment JZP815

(Alliance News) - Redx Pharma PLC on Wednesday said the US Food & Drug Administration has cleared the investigational new drug application for JZP815, a pan-RAF inhibitor for the treatment of solid tumours and haematological malignancies.

Read more
19 May 2022 18:55

TRADING UPDATES: Knights tips revenue hike; Gym Group eyes growth

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 May 2022 19:37

IN BRIEF: Redx Pharma to raise GBP30 million to fund pipelines

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Proposes to raise GBP30 million through a placing to institutional investors of shares at a price of 59 pence each.

Read more
8 Apr 2022 19:41

IN BRIEF: Redx Pharma notes "encouraging" RXC004 data in cancer

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes "encouraging" preclincal data for RXC004 as a targeted therapy for Wnt-ligand driven cancer.

Read more
5 Apr 2022 21:39

TRADING UPDATES: Alpha FX restarts relationship; Atalaya resources up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 11:05

IN BRIEF: Redx Pharma to start new Crohn's disease study in late 2023

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Announces end of 2023 as start of phase 1 studies for its Crohn's disease clinical development candidate RXC008. The inhibitor is designed to act exclusively in the gastrointestinal tract at the site of fibrosis in Crohn's disease patients. Up to 50% of patients with Crohn's disease can develop significant fibrosis, the company says, citing a 2013 study published by the National Center for Biotechnology Information based in Bethesda, Maryland, United States.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.